Comparative cardiovascular safety of glucagon‐like peptide‐1 receptor agonists versus other antidiabetic drugs in routine care: a cohort study
The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
Aims: To evaluate the comparative cardiovascular disease ( CVD ) safety of glucagon‐like peptide‐1 receptor agonists ( GLP ‐1 RAs ) in head‐to‐head comparisons with dipeptidyl peptidase‐4 ( DPP ‐4) inhibitors, sulphonylureas or insulin, when added to metformin, as used in ‘real‐world’ patients with type 2 diabetes mellitus ( T2DM ). Methods: Within a large US commercial health plan database linked to laboratory test results, we identified three pairwise 1 : 1 propensity‐score‐matched cohorts of patients with T2DM aged ≥18 years treated with metformin who initiated a GLP ‐1 RA or a comparator, i.e. DPP ‐4 inhibitor (n = 35 534), second‐generation sulphonylureas (n = 28 138) or insulin (n = 47 068), between 2005 and 2013. We examined the association between drug initiation and a composite CVD endpoint, comprising hospitalizations for acute myocardial infarction, unstable angina, stroke or coronary revascularization. Results: During the course of 1 year, there were 13.9 and 13.7 CVD events per 1000 person‐years among propensity‐score‐matched initiators of GLP ‐1 RAs versus DPP ‐4 inhibitors [hazard ratio ( HR ) 1.02; 95% confidence interval ( CI ) 0.84–1.24]; and 12.1 versus 14.0 events among initiators of GLP ‐1 RAs versus sulphonylureas ( HR 0.86; 95% CI 0.69–1.08). The effect estimates for GLP ‐1 RAs versus insulin were sensitive to the adjustment for glycated haemoglobin, after which the HR was 1.01 (95% CI 0.73–1.41). Results were robust across several sensitivity analyses, including an as‐treated analysis considering up to 8.7 years of follow‐up. Conclusions: This large study, performing head‐to‐head comparisons of GLP ‐1 RAs with other antidiabetic agents in real‐world patients, provides estimates of relative safety precise enough to exclude large differences in CVD risk and adds further understanding to results from recent clinical trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2015) · Diabetes Care · doi:10.2337/dc14-2441 · Cited by 3,066 · cited 1×
“To the extent possible, we designed our observational study like a randomized trial, including drug initiators and comparing treatment strategies similarly recommended by medical guidelines [37].”
MethodEffect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes
Green, J. B., Bethel, M. A., Armstrong, P. W., Buse, J. B., Engel, S. S., Garg, J., Josse, R., Kaufman, K. D., Koglin, J., Korn, S., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501352 · Cited by 2,577
Alogliptin after acute coronary syndrome in patients with type 2 diabetes
White, W. B., Cannon, C. P., Heller, S. R., Nissen, S. E., Bergenstal, R. M., Bakris, G. L., Perez, A. T., Fleck, P. R., Mehta, C. R., Kupfer, S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305889 · Cited by 2,502
Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome
Pfeffer, M. A., Claggett, B., Diaz, R., Dickstein, K., Gerstein, H. C., Køber, L. V., Lawson, F. C., Ping, L., Wei, X., Lewis, E. F., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1509225 · Cited by 2,409 · cited 2×
“Pooled analyses of early, small randomized clinical trials, showed trends toward a potential reduction in cardiovascular events associated with GLP-1 RAs, although this effect failed to reach statistical significance [12–14]; however, the ELIXA trial, the first completed cardiovascular outcome trial examining GLP-1 RA…”
BackgroundResultRomano, P. S., Roos, L. L., & Jollis, J. G. (1993) · Journal of Clinical Epidemiology · doi:10.1016/0895-4356(93)90103-8 · Cited by 1,717
Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus
Selvin, E., Marinopoulos, S., Berkenblit, G., Rami, T., Brancati, F. L., Powe, N. R., & Golden, S. H. (2004) · Annals of Internal Medicine · doi:10.7326/0003-4819-141-6-200409210-00007 · Cited by 1,657
Schneeweiss, S., Rassen, J. A., Glynn, R. J., Avorn, J., Mogun, H., & Brookhart, M. A. (2009) · Epidemiology · doi:10.1097/ede.0b013e3181a663cc · Cited by 1,128 · cited 2×
“Empirical studies have shown that the high-dimensional propensity score algorithm improves adjustment for unmeasured confounding [28,29].”
BackgroundMethodSelf-citationBoussageon, R., Bejan-Angoulvant, T., Saadatian-Elahi, M., Lafont, S., Bergeonneau, C., Kassai, B., Erpeldinger, S., Wright, J. M., Gueyffier, F., & Cornu, C. (2011) · BMJ · doi:10.1136/bmj.d4169 · Cited by 803 · cited 1×
“Yet the beneficial effects of intensive glycaemic control on cardiovascular risk remain controversial [6].”
BackgroundRobinson, L. E., Holt, T. A., Rees, K., Randeva, H. S., & O'Hare, J. P. (2013) · BMJ Open · doi:10.1136/bmjopen-2012-001986 · Cited by 296 · cited 1×
“GLP-1 RAs have, however, also been associated with a small but significant increase in heart rate [10,11].”
BackgroundCostanzo, P., Cleland, J. G. F., Pellicori, P., Clark, A. L., Hepburn, D., Kilpatrick, E. S., Perrone-Filardi, P., Zhang, J., & Atkin, S. L. (2015) · Annals of Internal Medicine · doi:10.7326/m14-1551 · Cited by 199 · cited 10×
“Using three propensity-score-matched cohorts that included >70 000 unique patients with T2DM from a large commercial US health insurance database, we found no significant difference in occurrence of CVD endpoints associated with initiation of GLP-1 RAs compared with initiation of DPP-4 inhibitors, second-generation su…”
BackgroundInfluential
Cited by
When and how can real world data analyses substitute for randomized controlled trials?
Franklin, J. M., & Schneeweiss, S. (2017) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.857 · Cited by 316
Glucagon-like peptide-1 receptor agonists: a systematic review of comparative effectiveness research
Levin, P. A., Nguyen, H., Wittbrodt, E., & Kim, S. C. (2017) · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy · doi:10.2147/dmso.s130834 · Cited by 107
Self-citationSocioeconomic aspects of incretin-based therapy
Karagiannis, T., Bekiari, E., & Tsapas, A. (2023) · Diabetologia · doi:10.1007/s00125-023-05962-z · Cited by 91
Caruso, I., Cignarelli, A., Sorice, G. P., Natalicchio, A., Perrini, S., Laviola, L., & Giorgino, F. (2022) · Metabolites · doi:10.3390/metabo12020183 · Cited by 86
“failed to show any superiority of GLP-1RA over DPP-4i, sulphonylureas, and insulin, but the majority of GLP-1RA initiators were on exenatide bis in die [20].”
BackgroundInfluentialMaskery, M. P., Holscher, C., Jones, S. P., Price, C. I., Strain, W. D., Watkins, C. L., Werring, D. J., & Emsley, H. C. (2021) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x20952011 · Cited by 51
Metadata
- Authors
- Patorno, E., Everett, B. M., Goldfine, A. B., Glynn, R. J., Liu, J., Gopalakrishnan, C., & Kim, S. C.
- Venue
- Diabetes, Obesity and Metabolism
- Publisher
- Wiley
- Published
- 2016-05-02
- Volume
- 18
- Issue
- 8
- Pages
- 755-765
- ISSN
- 1462-8902 (ISSN-L)
- 1463-1326
- OpenAlex
- W2307586345
- Cited by
- 31
- References
- 10
- FWCI
- 3.18
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.